APO Research
Talk to an analyst

APO RESEARCH · REPORT

PDGFRα/β Multikinase Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PDGFRα/β Multikinase Antagonists Market Outlook and Growth Opportunities 2026

29 December 2025197 pages

Choose your research edition.

Industry ResearchPDGFRα/β Multikinase Antagonists Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal PDGFRα/β Multikinase Antagonists Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal PDGFRα/β Multikinase Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PDGFRα/β Multikinase Antagonists Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PDGFRα/β Multikinase Antagonists Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global PDGFRα/β Multikinase Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PDGFRα/β Multikinase Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PDGFRα/β Multikinase Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PDGFRα/β Multikinase Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PDGFRα/β Multikinase Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PDGFRα/β Multikinase Antagonists market include Il-Yang Pharmaceutical, Takeda, Eisai, Novartis, Eli Lilly, Pfizer, GSK, Boehringer Ingelheim and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global PDGFRα/β Multikinase Antagonists market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PDGFRα/β Multikinase Antagonists and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PDGFRα/β Multikinase Antagonists revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global PDGFRα/β Multikinase Antagonists market.

PDGFRα/β Multikinase Antagonists Segment by Company

Il-Yang Pharmaceutical

Takeda

Eisai

Novartis

Eli Lilly

Pfizer

GSK

Boehringer Ingelheim

Bayer

Bristol-Myers Squibb

PDGFRα/β Multikinase Antagonists Segment by Type

Capsules

Tablets

Others

PDGFRα/β Multikinase Antagonists Segment by Application

Hospitals

Clinics

PDGFRα/β Multikinase Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PDGFRα/β Multikinase Antagonists status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the PDGFRα/β Multikinase Antagonists key companies, revenue, market share, and recent developments.

3. To split the PDGFRα/β Multikinase Antagonists breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions PDGFRα/β Multikinase Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PDGFRα/β Multikinase Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze PDGFRα/β Multikinase Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PDGFRα/β Multikinase Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PDGFRα/β Multikinase Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PDGFRα/β Multikinase Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PDGFRα/β Multikinase Antagonists industry.

Chapter 3: Detailed analysis of PDGFRα/β Multikinase Antagonists company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of PDGFRα/β Multikinase Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of PDGFRα/β Multikinase Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PDGFRα/β Multikinase Antagonists Industry Trends Table 2. PDGFRα/β Multikinase Antagonists Industry Drivers Table 3. PDGFRα/β Multikinase Antagonists Industry Opportunities and Challenges Table 4. PDGFRα/β Multikinase Antagonists Industry Restraints Table 5. Global PDGFRα/β Multikinase Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PDGFRα/β Multikinase Antagonists Revenue Share by Company (2021-2026) Table 7. Global PDGFRα/β Multikinase Antagonists Company Ranking, (2024-2026) & (US$ Million) Table 8. Global PDGFRα/β Multikinase Antagonists Key Company Manufacturing Base & Headquarters Table 9. Global PDGFRα/β Multikinase Antagonists Company, Product Type & Application Table 10. Global PDGFRα/β Multikinase Antagonists Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global PDGFRα/β Multikinase Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Capsules Table 15. Significant Companies of Tablets Table 16. Significant Companies of Others Table 17. Global PDGFRα/β Multikinase Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global PDGFRα/β Multikinase Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global PDGFRα/β Multikinase Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Type (2021-2026) Table 21. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Clinics Table 24. Global PDGFRα/β Multikinase Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global PDGFRα/β Multikinase Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global PDGFRα/β Multikinase Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Application (2021-2026) Table 28. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Application (2027-2032) Table 29. Global PDGFRα/β Multikinase Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global PDGFRα/β Multikinase Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Region (2021-2026) Table 32. Global PDGFRα/β Multikinase Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Region (2027-2032) Table 34. Global PDGFRα/β Multikinase Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global PDGFRα/β Multikinase Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global PDGFRα/β Multikinase Antagonists Sales Value Market Share by Country (2021-2026) Table 37. Global PDGFRα/β Multikinase Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global PDGFRα/β Multikinase Antagonists Sales Value Market Share by Country (2027-2032) Table 39. Il-Yang Pharmaceutical Company Information Table 40. Il-Yang Pharmaceutical Business Overview Table 41. Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Product Portfolio Table 43. Il-Yang Pharmaceutical Recent Development Table 44. Takeda Company Information Table 45. Takeda Business Overview Table 46. Takeda PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Takeda PDGFRα/β Multikinase Antagonists Product Portfolio Table 48. Takeda Recent Development Table 49. Eisai Company Information Table 50. Eisai Business Overview Table 51. Eisai PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Eisai PDGFRα/β Multikinase Antagonists Product Portfolio Table 53. Eisai Recent Development Table 54. Novartis Company Information Table 55. Novartis Business Overview Table 56. Novartis PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis PDGFRα/β Multikinase Antagonists Product Portfolio Table 58. Novartis Recent Development Table 59. Eli Lilly Company Information Table 60. Eli Lilly Business Overview Table 61. Eli Lilly PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Eli Lilly PDGFRα/β Multikinase Antagonists Product Portfolio Table 63. Eli Lilly Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pfizer PDGFRα/β Multikinase Antagonists Product Portfolio Table 68. Pfizer Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GSK PDGFRα/β Multikinase Antagonists Product Portfolio Table 73. GSK Recent Development Table 74. Boehringer Ingelheim Company Information Table 75. Boehringer Ingelheim Business Overview Table 76. Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Product Portfolio Table 78. Boehringer Ingelheim Recent Development Table 79. Bayer Company Information Table 80. Bayer Business Overview Table 81. Bayer PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bayer PDGFRα/β Multikinase Antagonists Product Portfolio Table 83. Bayer Recent Development Table 84. Bristol-Myers Squibb Company Information Table 85. Bristol-Myers Squibb Business Overview Table 86. Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Product Portfolio Table 88. Bristol-Myers Squibb Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. PDGFRα/β Multikinase Antagonists Product Image Figure 2. Global PDGFRα/β Multikinase Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PDGFRα/β Multikinase Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global PDGFRα/β Multikinase Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Capsules Image Figure 8. Tablets Image Figure 9. Others Image Figure 10. Global PDGFRα/β Multikinase Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global PDGFRα/β Multikinase Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Clinics Image Figure 15. Global PDGFRα/β Multikinase Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global PDGFRα/β Multikinase Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Application (2021-2032) Figure 18. Global PDGFRα/β Multikinase Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global PDGFRα/β Multikinase Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America PDGFRα/β Multikinase Antagonists Sales Value (2021-2032) & (US$ Million) Figure 21. North America PDGFRα/β Multikinase Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe PDGFRα/β Multikinase Antagonists Sales Value (2021-2032) & (US$ Million) Figure 23. Europe PDGFRα/β Multikinase Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific PDGFRα/β Multikinase Antagonists Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific PDGFRα/β Multikinase Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America PDGFRα/β Multikinase Antagonists Sales Value (2021-2032) & (US$ Million) Figure 27. South America PDGFRα/β Multikinase Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa PDGFRα/β Multikinase Antagonists Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa PDGFRα/β Multikinase Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Capsules
  • Tablets
  • Others
Applications
  • Hospitals
  • Clinics
Companies covered
  • Il-Yang Pharmaceutical
  • Takeda
  • Eisai
  • Novartis
  • Eli Lilly
  • Pfizer
  • GSK
  • Boehringer Ingelheim
  • Bayer
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PDGFRα/β Multikinase Antagonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PDGFRα/β Multikinase Antagonists Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 PDGFRα/β Multikinase Antagonists Market Dynamics
  1. 2.1 PDGFRα/β Multikinase Antagonists Industry Trends
  2. 2.2 PDGFRα/β Multikinase Antagonists Industry Drivers
  3. 2.3 PDGFRα/β Multikinase Antagonists Industry Opportunities and Challenges
  4. 2.4 PDGFRα/β Multikinase Antagonists Industry Restraints
3 PDGFRα/β Multikinase Antagonists Market by Company
  1. 3.1 Global PDGFRα/β Multikinase Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global PDGFRα/β Multikinase Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global PDGFRα/β Multikinase Antagonists Company Ranking (2024-2026)
  4. 3.4 Global PDGFRα/β Multikinase Antagonists Company Manufacturing Base and Headquarters
  5. 3.5 Global PDGFRα/β Multikinase Antagonists Company Product Type and Application
  6. 3.6 Global PDGFRα/β Multikinase Antagonists Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global PDGFRα/β Multikinase Antagonists Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 PDGFRα/β Multikinase Antagonists Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 PDGFRα/β Multikinase Antagonists Market by Type
  1. 4.1 PDGFRα/β Multikinase Antagonists Type Introduction
  2. 4.1.1 Capsules
  3. 4.1.2 Tablets
  4. 4.1.3 Others
  5. 4.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Type
  6. 4.2.1 Global PDGFRα/β Multikinase Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Type (2021-2032)
  8. 4.2.3 Global PDGFRα/β Multikinase Antagonists Sales Value Share by Type (2021-2032)
5 PDGFRα/β Multikinase Antagonists Market by Application
  1. 5.1 PDGFRα/β Multikinase Antagonists Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Application
  5. 5.2.1 Global PDGFRα/β Multikinase Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Application (2021-2032)
  7. 5.2.3 Global PDGFRα/β Multikinase Antagonists Sales Value Share by Application (2021-2032)
6 PDGFRα/β Multikinase Antagonists Regional Value Analysis
  1. 6.1 Global PDGFRα/β Multikinase Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Region (2021-2032)
  3. 6.2.1 Global PDGFRα/β Multikinase Antagonists Sales Value by Region: 2021-2026
  4. 6.2.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PDGFRα/β Multikinase Antagonists Sales Value (2021-2032)
  7. 6.3.2 North America PDGFRα/β Multikinase Antagonists Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe PDGFRα/β Multikinase Antagonists Sales Value (2021-2032)
  10. 6.4.2 Europe PDGFRα/β Multikinase Antagonists Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific PDGFRα/β Multikinase Antagonists Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific PDGFRα/β Multikinase Antagonists Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America PDGFRα/β Multikinase Antagonists Sales Value (2021-2032)
  16. 6.6.2 South America PDGFRα/β Multikinase Antagonists Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa PDGFRα/β Multikinase Antagonists Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa PDGFRα/β Multikinase Antagonists Sales Value Share by Country, 2025 VS 2032
7 PDGFRα/β Multikinase Antagonists Country-level Value Analysis
  1. 7.1 Global PDGFRα/β Multikinase Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Country (2021-2032)
  3. 7.2.1 Global PDGFRα/β Multikinase Antagonists Sales Value by Country (2021-2026)
  4. 7.2.2 Global PDGFRα/β Multikinase Antagonists Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt PDGFRα/β Multikinase Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt PDGFRα/β Multikinase Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt PDGFRα/β Multikinase Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Il-Yang Pharmaceutical
  2. 8.1.1 Il-Yang Pharmaceutical Company Information
  3. 8.1.2 Il-Yang Pharmaceutical Business Overview
  4. 8.1.3 Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Product Portfolio
  6. 8.1.5 Il-Yang Pharmaceutical Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda PDGFRα/β Multikinase Antagonists Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Eisai
  14. 8.3.1 Eisai Company Information
  15. 8.3.2 Eisai Business Overview
  16. 8.3.3 Eisai PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eisai PDGFRα/β Multikinase Antagonists Product Portfolio
  18. 8.3.5 Eisai Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis PDGFRα/β Multikinase Antagonists Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly PDGFRα/β Multikinase Antagonists Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer PDGFRα/β Multikinase Antagonists Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GSK
  38. 8.7.1 GSK Company Information
  39. 8.7.2 GSK Business Overview
  40. 8.7.3 GSK PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GSK PDGFRα/β Multikinase Antagonists Product Portfolio
  42. 8.7.5 GSK Recent Developments
  43. 8.8 Boehringer Ingelheim
  44. 8.8.1 Boehringer Ingelheim Company Information
  45. 8.8.2 Boehringer Ingelheim Business Overview
  46. 8.8.3 Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Product Portfolio
  48. 8.8.5 Boehringer Ingelheim Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer PDGFRα/β Multikinase Antagonists Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst